Benitec Biopharma EPS
The Earnings per Share (EPS) of Benitec Biopharma (BNTC) as of Oct 20, 2026 is -1.05 USD. In the previous year, Earnings per Share (EPS) was -5.51 USD — a change of -80.99% (higher).
Get this data via API
Financial Data API
EPS
-1.05USD
YoY
-80.99%
Last updated:
The Benitec Biopharma EPS history
3 Years
10 Years
25 Years
Max
| YEAR | EPS | YoY |
|---|---|---|
| est | 0.24USD | -114.77% |
| est | -1.63USD | +17.75% |
| est | -1.38USD | -3.72% |
| est | -1.43USD | +19.02% |
| est | -1.20USD | +23.10% |
| est | -0.98USD | -6.57% |
| -1.05USD | -80.99% | |
| -5.51USD | -60.85% | |
| -14.07USD | -62.91% | |
| -37.94USD | -31.67% | |
| -55.52USD | -59.72% | |
| -137.83USD | -47,518.43% | |
| 0.29USD | -126.59% | |
| -1.09USD | +75.34% | |
| -0.62USD | -70.78% | |
| -2.13USD | +52.95% | |
| -1.40USD | +15.97% | |
| -1.20USD | -16.67% | |
| -1.44USD | -23.06% | |
| -1.88USD | -33.88% | |
| -2.84USD | -22.11% | |
| -3.64USD | +80.14% | |
| -2.02USD | -30.69% | |
| -2.92USD | -14.90% | |
| -3.43USD | -71.33% | |
| -11.96USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Benitec Biopharma Stock analysis
Frequently Asked Questions about Benitec Biopharma stock
Earnings per Share (EPS) of Benitec Biopharma is -1.05 USD in 2025.
Earnings per Share (EPS) of Benitec Biopharma changed from -5.51 USD to -1.05 USD, representing a -80.99% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Benitec Biopharma since 2006 – with annual values, charts, and detailed analysis.
Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.
EPS = Net Income / Shares Outstanding
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Benitec Biopharma
All Key Metrics — Benitec Biopharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth